Objective-To assess the effectiveness of angiotensin converting enzyme inhibition in preventing
Introduction
Roughly 35% of all insulin dependent diabetic patients develop diabetic nephropathy. This clinical syndrome is characterised by persisent albuminuria >300 mg/24 h, a relentless decline in the glomerular filtration rate, and raised arterial blood pressure. ' 2 The mortality in patients suffering from diabetic nephropathy is up to 100 times that of the age and sex matched background population, and this is mainly due to an enormous excess of deaths from end stage renal disease.' Arterial hypertension enhances the development of diabetic glomerulopathy, and antihypertensive treatment reduces albuminuria and diminishes the rate of decline in the glomerular filtration rate, thereby postponing end stage renal failure in patients with diabetic nephropathy. [4] [5] [6] During the past decade the prognosis of diabetic nephropathy has improved substantially, probably as a consequence of early and aggressive antihypertensive treatment.7 Nevertheless, diabetic nephropathy is still the single most important cause of end stage renal disease in the Western World, accounting for over a quarter of all end stage renal disease in the United States. Thus there is an urgent need to evaluate treatments which may delay or even prevent the development of diabetic nephropathy in the subpopulation at risk.
The insulin dependent diabetes mellitus subpopulation at risk may now be identified fairly accurately by the detection of microalbuminuria. Longitudinal studies have shown that raised urinary albumin excretion below the level of clinical albuminuria -so called microalbuminuria-strongly predicts the development of nephropathy in insulin dependent diabetes.9 12 The prevalence of microalbuminuria, defined as urinary albumin excretion between 30 and 300 mg/24 h,'3 was around 20% in a large diabetic clinic.'4 "5 The development and progression of microalbuminuria is associated with poor metabolic control.'4-' 7 We have found that near normal blood glucose control achieved with insulin pumps can delay the development of diabetic nephropathy and thus preserve a normal and stable glomerular filtration rate in patients with persistent microalbuminuria." Unfortunately, severe and even lethal side effectsfor example, hypoglycaemia and ketoacidosis-are reported more often. [18] [19] [20] A small increase in arterial blood pressure is an early and common finding in patients with microalbuminuria.'2 '4 1621 A rise in systemic blood pressure transmitted to the glomerular capillary network results in glomerular hypertension,22 which has also been shown in most normotensive rats with streptozotocin induced diabetes.23 A link between raised intraglomerular pressure and albuminuria and the development and progression of diabetic renal disease has been reported. 24 25 Acute reduction of systemic blood pressure in normotensive patients with persistent microalbuminuria reduces urinary albumin excretion,26 probably owing to a reduction in intraglomerular pressure. In diabetic Wistar rats angiotensin converting enzyme inhibition reduces glomerular hypertension, restricts the increase in urinary albumin excretion, and slows the development of glomerular structural lesions. 23 We report a four year prospective randomised controlled trial aimed at evaluating the effect of angiotensin converting enzyme inhibition on the development of diabetic nephropathy in normotensive insulin dependent diabetic patients with persistent microalbuminuria. Captopril was chosen because it is effective and well tolerated in hypertensive patients with diabetic nephropathy.
Patients and methods
We examined the records of all insulin dependent diabetic patients with microalbuminuria (n=220) above the age of 17 
Results
The baseline values in the two groups are given in tables I (5) 19 (7) Fractional albumin clearance (x 10) 11-4(0 9-67) 8-8(2-4-72) Glomerular filtration rate (ml/min) 129 (18) 126 (24) Haemoglobin Al, (%) (1-4) (p<0 05; fig 1) . From the 24th month the change in urinary albumin excretion from baseline was persistently lower in the captopril group than in the controls (p<OOS). Table III compares the mean annual changes in urinary albumin excretion, fractional urinary albumin clearance, blood pressure, and glomerular filtration rate between the two groups. Urinary albumin excretion and fractional albumin clearance had fallen by an average of 9% and 16% a year over the four years in the captopril treated group whereas rises of 8% and 6% a year were found in BMJ VOLUME 303 13 (fig 1; table III) . The annual decline in the glomerular filtration rate in the captopril and control groups was small (1 4 and 0 6 ml/min), with no differences between the groups (table III) .
Seven of the untreated patients had progressed to diabetic nephropathy compared with none of the captopril treated group (p<0-05; table II). Of the seven patients developing nephropathy, one had had a baseline urinary albumin excretion value below 60 mg/24 h, three baseline values of 60-150 mg/24 h, and three baseline values above 150 mg/24 h (table II) . In these seven patients the mean increase in urinary albumin excretion was 27% a year (-3% to 57%o (95% confidence interval)). The mean rate of decline in their glomerular filtration rate was 4 0 (-1 to 9) ml/min a year (p=0 08) and their mean increase in blood pressure 2 (-I to 5)/1 (-I to 3) mm Hg a year. Captopril group z, controls: *p<005., **p<001, ***p<0 001.
these patients had a substantial decline in their glomerular filtration rate (5 and 15 ml/min a year). In the captopril treated group no patient had a substantial decline in the glomerular filtration rate. The renin-angiotensin system showed a suppressed plasma concentration of angiotensin II and increased values of angiotensin I and renin in the captopril treated group, indicating substantial inhibition of angiotensin converting enzyme activity (table IV) . Metabolic control and urinary excretion of urea did not differ between the two groups at any time during the study (fig 2) . No significant changes were observed in the body weight, plasma volume, extracellular fluid volume, serum lipid concentrations, or leucocyte count (table V) . Serum potassium concentration and urinary excretion of sodium remained constant during captopril treatment, with a minor decline after diuretics were added.
During treatment with both captopril and thiazide the ambulatory 24 hour blood pressure profiles showed significantly lower diastolic pressure at 0900 and between 1900 and 2300. At 2100, 2300, and 0100 the systolic blood pressure was significantly lower. At other times no significant differences could be detected in systolic or diastolic blood pressure (fig 3) . From the total area below the curve the average blood pressure during the were obtained despite failure to achieve our treatment goal. We strived to obtain a reduction in diastolic blood pressure by increasing the dose of captopril to 100 mg/24 h and adding a diuretic, but did not succeed. Our results confirm and extend those of Marre et al.4 They found that enalapril (20 mg/day) for one year induced a progressive reduction in urinary albumin excretion in 10 normotensive diabetic patients with persistent microalbuminuria. Three ofthe 10 untreated diabetics developed persistent albuminuria. Both insulin dependent and non-insulin dependent diabetic patients were enrolled in that study.
The reduction in urinary albumin excretion observed in our series was not caused by a decrease in the glomerular filtration rate or serum albumin concentration as the changes in fractional albumin clearance were proportional to the fall in urinary albumin excretion. Several studies have shown that tubular protein reabsorption-as estimated, for example, with li2 microglobulin-is normal in patients with microalbuminuria.'242 We emphasise that haemoglobin Alc concentration, serum cholesterol and triglyceride concentrations, protein intake, urinary sodium excretion, and body weight remained nearly identical in the two groups during the four years. Energy, sodium, and protein restriction was not applied in our study. Treatment with prostaglandin inhibitors was avoided. Analysis of covariance showed that the imbalance in the four matching factors at baseline did not affect the observed differences in urinary albumin excretion between the two groups. Thus we can rule out these confounding factors. 18 43 44 Though systemic blood pressure was unchanged both during angiotensin converting enzyme inhibition and after the addition of diuretics in our study, Marre et al found a significant drop.4' This disparity may well be explained by the higher systemic blood pressure at baseline and the lower urinary sodium excretion in the study of Marre et al. We measured blood pressure at least six hours after the last antihypertensive dose. The possibility that blood pressure might have been depressed during the remainder ofthe day was excluded by the ambulatory 24 hour profiles.
The significant effect on urinary albumin excretion was shown with angiotensin converting enzyme inhibition alone. Adding diuretics in the captopril group possibly reduced 24 hour urinary albumin excretion a little further (NS), but a longer observation period will be necessary before the clinical relevance of adding diuretics can be evaluated.
MECHANISMS OF ANTIPROTEINURIC EFFECT
The observed antiproteinuric effect of angiotensin converting enzyme inhibition may be due either to reduced efferent arteriolar resistance leading to diminished glomerular capillary hydraulic pressure or to enhanced intrinsic selectivity of the glomerular barrier wall, or to both. The slow and gradual reduction in microalbuminuria observed during angiotensin converting enzyme inhibition in this and other studies4' suggests a progressive reduction in the permeability of the glomerular barrier to protein. In diabetic rats converting enzyme inhibition prevents the development of albuminuria and restricts mesangial volume expansion and focal glomerulosclerosis.234' This effect was associated with a reduction of the raised intraglomerular pressure, but in another model of experimental chronic renal disease inhibition of angiotensin II attenuated the accumulation of macromolecules in the mesangium independently of changes in intraglomerular pressure.46 Inhibition of glomerular basal membrane thickening with converting enzyme inhibition in diabetic rats has also been described. 47 Morelli et al have studied the sieving profile of neutral dextran during angiotensin converting enzyme inhibition (enalapril) in 16 normotensiv-e insulin dependent diabetic patients with urinary albumin excretion exceeding 50 [ig/min.4" Angiotensin converting enzyme inhibition for 90 days significantly reduced the fractional dextran clearance and systemic blood pressure. Using a heteroporous model of the glomerular barrier and assuming either slightly reduced or unchanged transglomerular pressure, Morelli et al suggested that inhibiting converting enzyme enhances barrier size selectivity. The potential impact of angiotensin converting enzyme inhibition on charge selective properties remains to be elucidated.
Morphometric studies have shown a strong relation between mesangial expansion and the clinical manifestations of diabetic nephropathy'9 and an inverse correlation between the glomerular filtration rate and the glomerular filtration surface.50 A recent morphometric study found that insulin dependent diabetic patients with microalbuminuria and hypertension or reduced creatinine clearance, or both, have established abnormalities of the glomerular structure, including fractional mesangial expansion.5' This clearly indicates that microalbuminuria in association with other signs of renal dysfunction can be a marker of diabetic glomerulopathy. The authors, however, also reported that microalbuminuria without these functional abnormalities is not a marker of underlying glomerular lesions5' and so must be regarded as a predictor of the later development of diabetic nephropathy as originally suggested. [9] [10] [11] [12] At baseline all patients in our study were normotensive and had a normal or slightly increased glomerular filtration rate. The suggestion that the development of clinical, overt diabetic nephropathy is a valid scientific end point is supported by the five to eight years' follow up of our prospective trials of 50 patients randomised to intensified treatment with insulin pumps or unchanged conventional insulin treatment.2" A significant reduction in the glomerular filtration rate (3-0 ml/min/year) was found in those patients who developed clinical nephropathy defined as in this study, whereas the glomerular filtration rate remained normal or supranormal for at least five to eight years in those who did not progress to diabetic nephropathy.2' In this study the rate of decline in the glomerular filtration rate was 4 0 ml/min/year in patients developing diabetic nephropathy and 0-9 ml/min/year in patients not developing overt albuminuria.
Conclusion
We conclude that angiotensin converting enzyme inhibition postpones the development of diabetic nephropathy in normotensive insulin dependent diabetic patients with persistent microalbuminuria. Longer follow up, however, is mandatory to see if this will result in preservation of the normal glomerular filtration rate and improved survival without severe side effects before angiotensin converting enzyme inhibition can be advocated in these patients. Results-Blood echogenicity correlated poorly with the packed cell volume, but strongly correlated with the erythrocyte sedimentation rate (when the packed cell volume was within reference limits) (correlation coefficient = 0.73). Blood samples with a greatly raised erythrocyte sedimentation rate were highly echogenic. Only one of the 30 samples with an erythrocyte sedimentation rate below 10 mm in first hour had a higher echogenicity than the least echogenic sample of the 19 with a sedimentation rate above 30 mm in first hour.
Conclusions-Echogenicity of flowing blood correlates with the erythrocyte sedimentation rate and its measurement may compete with conventional methods for evaluating the long term changes in acute phase reactions. Also, it has the added advantage that non-invasive in vivo measurements of blood echogenicity may become possible.
Introduction
The plasma concentration of macromolecules increases during the acute phase response to infection. This enhances the aggregation of red blood cells, raising the amount of sedimentation.' The rate of erythrocyte sedimentation is used as a universal routine screening test and a measure of the progress of some inflammatory diseases. The reliability of the test is hampered by its dependence on packed cell volume and lack of specificity; several methods have been developed to overcome these disadvantages, but none has gained wide use. 
